{"id":"6737844d-0cad-51d2-a488-d329dd308d3f","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-rabbit-platelets","predicate":"decreases_in_recorded_comparison","statement":"RA reduced arachidonic-acid-, ADP- and collagen-induced aggregation in isolated rabbit platelet-rich plasma.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"331dddeb-8e6d-56e0-b651-c9300fb3edf7","mechanism_event_label":"RA reduced arachidonic-acid-, ADP- and collagen-induced aggregation in isolated rabbit platelet-rich plasma.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"3011d889-6314-5fa8-9090-718932a4f09b","slug":"rabbit-platelet-aggregation","display_name":"Rabbit platelet aggregation, agonist specified","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"331dddeb-8e6d-56e0-b651-c9300fb3edf7","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-rabbit-platelets-event","event_type":"experimental_observation","label":"RA reduced arachidonic-acid-, ADP- and collagen-induced aggregation in isolated rabbit platelet-rich plasma.","description":"### ra-rabbit-platelets\n\nRA reduced arachidonic-acid-, ADP- and collagen-induced aggregation in isolated rabbit platelet-rich plasma.\nAgonists: AA 0.24 mM, ADP 9 micromolar, collagen 10 micrograms/mL. No oral human bleeding or anticoagulant-interaction trial.\nModel and exposure: 1–100 micromolar RA, 5-min pretreatment, agonist-specific comparisons.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen <i>(Salvia miltiorrhiza)</i>. | 2018 | https://pubmed.ncbi.nlm.nih.gov/29849736/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5941821/ | https://doi.org/10.1155/2018/9387568 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"RA plus platelet agonist","sequence_order":0,"notes":""},{"entity":{"id":"3011d889-6314-5fa8-9090-718932a4f09b","slug":"rabbit-platelet-aggregation","display_name":"Rabbit platelet aggregation, agonist specified","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"39f9446f-52a6-502d-b507-91137726f82c","slug":"arachidonic-acid","display_name":"AA","entity_type_key":"small_molecule"},"role":"one agonist","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"136c3764-1b93-5f79-8673-9001cab9bc3d","slug":"adp","display_name":"Adenosine diphosphate","entity_type_key":"small_molecule"},"role":"one agonist","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"RA plus platelet agonist\", \"comparator\": \"Same agonist with vehicle\", \"endpoint\": \"RA reduced arachidonic-acid-, ADP- and collagen-induced aggregation in isolated rabbit platelet-rich plasma.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"1–100 micromolar RA, 5-min pretreatment, agonist-specific comparisons.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"RA reduced arachidonic-acid-, ADP- and collagen-induced aggregation in isolated rabbit platelet-rich plasma.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen <i>(Salvia miltiorrhiza)</i>. | https://pubmed.ncbi.nlm.nih.gov/29849736/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5941821/ | https://doi.org/10.1155/2018/9387568","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-rabbit-platelets; Agonists: AA 0.24 mM, ADP 9 micromolar, collagen 10 micrograms/mL. No oral human bleeding or anticoagulant-interaction trial.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"6c49ec4c-c3bd-5ded-98df-484919043d7b","evidence_kind":"source_excerpt","locator":"Lines 570-576","start_line":570,"end_line":576,"excerpt":"### ra-rabbit-platelets\n\nRA reduced arachidonic-acid-, ADP- and collagen-induced aggregation in isolated rabbit platelet-rich plasma.\nAgonists: AA 0.24 mM, ADP 9 micromolar, collagen 10 micrograms/mL. No oral human bleeding or anticoagulant-interaction trial.\nModel and exposure: 1–100 micromolar RA, 5-min pretreatment, agonist-specific comparisons.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen <i>(Salvia miltiorrhiza)</i>. | 2018 | https://pubmed.ncbi.nlm.nih.gov/29849736/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5941821/ | https://doi.org/10.1155/2018/9387568 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"1–100 micromolar RA, 5-min pretreatment, agonist-specific comparisons.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}